Entero Chronic

Hauptinformation

  • Handelsname:
  • Entero Chronic®
  • Verwenden für:
  • Tiere
  • Art der Medizin:
  • Nahrungsergänzungsmittel

Dokumenten

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Entero Chronic®
    Schweiz
  • Sprache:
  • Deutsch

Therapeutische Informationen

  • Therapiebereich:
  • Ergänzungsfuttermittel für Hunde und Katzen

Weitere Informationen

Status

  • Quelle:
  • Institut für Veterinärpharmakologie
  • Letzte Änderung:
  • 22-01-2018

Packungsbeilage

New Vetline Sagl

Ergänzungsfuttermittel für Hunde und Katzen

Inhalt

Zusammensetzung

α-Butyro-Glucan Butirogen 62,5%, ein verdauungsresistentes Polysaccharid, aus dem, durch bakterielle

Fermentation, Butyrat entsteht. Mucopolysaccharide MPS Protect). 3%, β-Glucane und Mannan-

Oligosaccharide (MOS) 7,5%.

Zusatzstoffe:

Technologischer Futtermittelzusatzstoff: Bentonit

Inhaltsstoffe

Rohfaser

0,9%

Rohprotein

6,5%

Rohasche

16,1%

Rohfett

1,2%

Salzsäureunlösliche Asch

1,7%

Eigenschaften

Entero-Chronic

ist ein Ergänzungsfuttermittel zur Stabilisierung der Darmtätigkeit bzw. Darmfunktion.

Es enthält es α-Glucane aus modifizierter Stärke zur Förderung der enteralen Bildung von Buttersäure,

ein wichtiger Nährstoff für das Dickdarmepithel. Hefeextrakte und Oligosaccharide sind präbiotische

Substanzen mit einem positiven Einfluss auf die physiologische Darmflora. Mucopolysaccharide (aus

Knorpelextrakt vom Rind) sind Bestandteil des Films, der zum Schutz der Darmzellen die Schleimhaut

überzieht.

Anwendung / Gebrauch

Fütterungsempfehlung

Welpen und Kitten

0 - 5 kg ½ Beutel

Hunde und Katzen:0 - 5 kg ½ Beutel

Hunde und Katzen:6 - 15 kg 1 Beutel

Hunde:

16 - 35 kg 2 Beutel

Hunde:

> 36 kg 3 Beutel

Anwendungseinschränkungen

Entero-Chronic

ist ein sicheres Produkt. Es sind keine unerwünschten Wirkungen bekannt. Entero-

Chronic

kann, wenn nötig, auch über mehrere Monate verabreicht werden.

Wechselwirkungen

Es sind keine unerwünschten Wirkungen bekannt.

Sonstige Hinweise

Kühl und trocken und vor direktem Licht geschützt aufbewahren. Ausserhalb der Reichweite von Kindern

aufbewahren.

Handelsformen

Packung à 30 und 60 Beutel.

Netto Gewicht

Packung mit 30 Beutel 120 gr

Packung mit 60 Beutel 240 gr.

Verkaufsart: beim Tierarzt erhältlich

Hersteller

Bioiberica SA, Barcelona; www.bioiberica.com

Agroscope−Registrierungsnummer: CH 31796

Informationsstand: 12.12.2012

11-10-2018

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Published on: Wed, 10 Oct 2018 00:00:00 +0200 The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion re‐evaluating the safety of thermally oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (TOSOM) (E 479b) when used as a food additive. The Scientific Committee on Food (SCF) and the Joint FAO/WHO Expert Committee on Food Additives (JECFA) derived an acceptable daily intake (ADI) of 25 and 30 mg/kg body weight (bw) per day, respectively. There was n...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed

Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed

Published on: Thu, 16 Aug 2018 00:00:00 +0200 4,15‐Diacetoxyscirpenol (DAS) is a mycotoxin primarily produced by Fusarium fungi and occurring predominantly in cereal grains. As requested by the European Commission, the EFSA Panel on Contaminants in the Food Chain (CONTAM) assessed the risk of DAS to human and animal health related to its presence in food and feed. Very limited information was available on toxicity and on toxicokinetics in experimental and farm animals. Due to the limitations in the avai...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Protocol for the scientific opinion on the Tolerable Upper Intake Level of dietary sugars

Protocol for the scientific opinion on the Tolerable Upper Intake Level of dietary sugars

Published on: Fri, 10 Aug 2018 00:00:00 +0200 In June 2016, EFSA received a mandate from the national food competent authorities of five European countries (Denmark, Finland, Iceland, Norway and Sweden) to provide a dietary reference value (DRV) for sugars, with particular attention to added sugars. A draft protocol was developed with the aim of defining as much as possible beforehand the strategy that will be applied for collecting data, appraising the relevant evidence, and analysing and integrating t...

Europe - EFSA - European Food Safety Authority Publications

18-7-2018

Orphan designation:  Gevokizumab,  for the: Treatment of chronic non-infectious uveitis

Orphan designation: Gevokizumab, for the: Treatment of chronic non-infectious uveitis

On 12 March 2013, orphan designation (EU/3/13/1111) was granted by the European Commission to Les Laboratoires Servier, France, for gevokizumab for the treatment of chronic non-infectious uveitis.

Europe - EMA - European Medicines Agency

9-7-2018

Statement by FDA Commissioner Scott Gottlieb, M.D., on balancing access to appropriate treatment for patients with chronic and end-of-life pain with need to take steps to stem misuse and abuse of opioids

Statement by FDA Commissioner Scott Gottlieb, M.D., on balancing access to appropriate treatment for patients with chronic and end-of-life pain with need to take steps to stem misuse and abuse of opioids

FDA Commissioner statement on balancing access to appropriate treatment for patients with chronic and end-of-life pain with need to take steps to stem opioid misuse and abuse.

FDA - U.S. Food and Drug Administration

29-5-2018

Orphan designation:  Nilotinib,  for the: Treatment of chronic myeloid leukaemia

Orphan designation: Nilotinib, for the: Treatment of chronic myeloid leukaemia

Europe - EMA - European Medicines Agency

25-5-2018

Orphan designation:  Treprostinil sodium,  for the: Treatment of chronic thromboembolic pulmonary hypertension

Orphan designation: Treprostinil sodium, for the: Treatment of chronic thromboembolic pulmonary hypertension

On 8 February 2013, orphan designation (EU/3/13/1103) was granted by the European Commission to SciPharm S.a.r.L, Luxembourg, for treprostinil sodium for the treatment of chronic thromboembolic pulmonary hypertension.

Europe - EMA - European Medicines Agency

21-5-2018

FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure

FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure

FDA approves Doptelet (avatrombopag) to treat thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical procedure.

FDA - U.S. Food and Drug Administration

7-5-2018

Orphan designation:  Bosutinib,  for the: Treatment of chronic myeloid leukaemia

Orphan designation: Bosutinib, for the: Treatment of chronic myeloid leukaemia

Europe - EMA - European Medicines Agency

13-9-2018

 European Medicines Agency stakeholder interaction on the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH), European Medicines Agency, London, UK, From: 03-Dec-2018, To: 03-Dec-2018

European Medicines Agency stakeholder interaction on the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH), European Medicines Agency, London, UK, From: 03-Dec-2018, To: 03-Dec-2018

This workshop on the development of medicines for chronic non-infectious liver diseases, including primary biliary cholangitis, primary sclerosing cholangitis and nonalcoholic steatohepatitis, provides a platform for discussion on appropriate endpoints including validation of surrogate endpoints/biomarkers, suitable study populations, potentially adequate trial designs and the specific challenges with paediatric medicine development. The workshop will support the drafting of a reflection paper on regul...

Europe - EMA - European Medicines Agency

2-7-2018

Vancomycin ENTEROCAPS® 250 mg

Rote - Liste